Official safety communications, quality alerts, recalls and medication-safety explainers.
WHO confirms World AMR Awareness Week on 18–24 November 2026. Explore the One Health theme, antibiotic stewardship, IPC and a practical CHC action plan.
CDSCO’s September 2026 fludrocortisone–hypokalaemia ADR notification explained: mineralocorticoid mechanism, potassium and BP monitoring, safety documentation.
CDSCO’s 27 October 2026 public notice lists ONDLS digital monitoring for high-risk solvent supply chains. What is verified, what remains unclear and quality-system actions.
WHO #MedSafetyWeek 2–8 November 2026: practical suspected ADR recognition, documentation, reporting through India’s PvPI, and patient safety.
CDSCO’s 26 October 2026 notice concerns misleading or false claims for FatX solution marketed under a cosmetic registration. What clinicians and consumers should verify before aesthetic procedures.
CDSCO’s 26 October 2026 listing highlights a WHO alert concerning falsified DEFITELIO (defibrotide) batch 24GC01A identified in India. Practical verification, quarantine and reporting steps for hospital pharmacies.
Evidence-based naloxone guide: airway and ventilation first, adult/paediatric label-based injection doses, nasal spray instructions, concentration checks, monitoring and recurrent opioid toxicity.
CDSCO listed teneligliptin–bullous pemphigoid as an ADR signal on 21 September 2026. Understand the DPP-4 inhibitor class context, blistering symptoms and safe clinical response.
FDA is investigating increased allergic and hypersensitivity reactions linked to Yimmugo IGIV lot C795314 and recommends immediate cessation of use of affected stock.
A practical explanation of CDSCO Not of Standard Quality alerts, batch-level interpretation and safe institutional response.
